Chapter 3
Atypical Alzheimer's disease
Sharon J. Sha,
Gil D. Rabinovici,
Sharon J. Sha
University of California, San Francisco, San Francisco, CA, USA
Stanford Center for Memory Disorders, Stanford, CA, USA
Search for more papers by this authorGil D. Rabinovici
University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorSharon J. Sha,
Gil D. Rabinovici,
Sharon J. Sha
University of California, San Francisco, San Francisco, CA, USA
Stanford Center for Memory Disorders, Stanford, CA, USA
Search for more papers by this authorGil D. Rabinovici
University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorBook Editor(s):Michael D. Geschwind MD PhD,
Caroline Racine Belkoura PhD,
Michael D. Geschwind MD PhD
Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorCaroline Racine Belkoura PhD
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Search for more papers by this authorSummary
Pathologic Alzheimer's disease commonly presents with the phenotype of early episodic memory loss. Memory loss, however, is not the only manifestation of Alzheimer's disease pathology. Alzheimer's disease often presents as syndromes beginning with prominent language, visual, or executive/behavioral dysfunction. Some cases even can present as corticobasal syndrome. In this chapter, we first will briefly describe the typical clinical presentation of AD and then review several nonamnestic presentations. Clinicopathological correlations will be considered. All cases are based on actual patients seen in our memory disorder clinic at UCSF, with identifying features eliminated or altered to preserve anonymity.
References
- Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29(1–2): 125–132.
- Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2003 Summer; 15(3): 346–353.
- Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007 Oct; 130(Pt 10): 2636–2645.
- Green RC, Goldstein FC, Mirra SS, Alazraki NP, Baxt JL, Bakay RA. Slowly progressive apraxia in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1995 Sep; 59(3): 312–315.
- Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000 Mar; 123 Pt 3: 484–498.
- Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004 Oct 12; 63(7): 1168–1174.
- Renner JA, Burns JM, Hou CE, McKeel DW, Jr, Storandt M, Morris JC. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 2004 Oct 12; 63(7): 1175–1180.
- Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999 Sep 11; 53(4): 795–800.
- Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006 Jan; 59(1): 156–165.
- Mesulam M, Wicklund A, Johnson N, Rogalski E, Leger GC, Rademaker A, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008 Jun; 63(6): 709–719.
- Rebeiz JJ, Kolodny EH, Richardson EP, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968 Jan; 18(1): 20–33.
- Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol 1988 Jul; 45(7): 789–793.
- Mesulam MM. Primary progressive aphasia. Ann Neurol 2001 Apr; 49(4): 425–432.
- Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 2010 Oct; 88(4): 475–486.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's Disease. Neurology 1984 Jul; 34(7): 939–944.
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 May; 7(3): 263–269.
- Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13(6): 614–629.
- Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005 Dec 17; 366(9503): 2112–2117.
- Thies W, Bleiler L, Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013 Mar; 9(2): 208–245.
- Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S, Rabinovici GD, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009 Nov 10; 73(19): 1571–1578.
- Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004 Mar; 55(3): 335–346.
- Frisoni GB, Pievani M, Testa C, Sabattoli F, Bresciani L, Bonetti M, et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007 Mar; 130(Pt 3): 720–730.
- Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010 Feb; 133(Pt 2): 512–528.
- Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, Roeber S, et al. Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord 2010; 29(4): 371–378.
- Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001 May 8; 56(9): 1143–1153.
- Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 2012 Apr; 71(4): 266–273.
- Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007 Aug; 6(8): 734–746.
- Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002 Nov; 61(11): 935–946.
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82(4): 239–259.
- Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002 Jun 25; 58(12): 1791–1800.
- Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991 Apr; 41(4): 479–486.
- Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National institute on aging–Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8(1): 1–13.
- Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999 Sep; 65(3): 664–670.
- Mendez MF, McMurtray A. Frontotemporal dementia-like phenotypes associated with presenilin-1 mutations. Am J Alzheimers Dis Other Demen 2006 Aug–Sep; 21(4): 281–286.
- Margallo-Lana M, Morris CM, Gibson AM, Tan AL, Kay DW, Tyrer SP, et al. Influence of the amyloid precursor protein locus on dementia in Down syndrome. Neurology 2004 Jun 8; 62(11): 1996–1998.
- Jarvik G, Larson EB, Goddard K, Schellenberg GD, Wijsman EM. Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. Am J Hum Genet 1996 Jan; 58(1): 191–200.
- Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994 Jun; 7(2): 180–184.
- Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease centers consortium on apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998 Feb 19; 338(8): 506–511.
- Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993 Aug; 43(8): 1467–1472.
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993 Aug 13; 261(5123): 921–923.
- van der Flier WM, Schoonenboom SN, Pijnenburg YA, Fox NC, Scheltens P. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006 Aug 8; 67(3): 526–527.
- Schott JM, Ridha BH, Crutch SJ, Healy DG, Uphill JB, Warrington EK, et al. Apolipoprotein E genotype modifies the phenotype of Alzheimer disease. Arch Neurol 2006 Jan; 63(1): 155–156.
- Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14(1): 33–40.
- Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015; 77(1): 43–51.
- Rabinovici GD, Seeley WW, Kim EJ, Gorno-Tempini ML, Rascovsky K, Pagliaro TA, et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2007 Dec–2008 Jan; 22(6): 474–488.
- Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009 Apr 16; 62(1): 42–52.
- Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000 Nov; 41(11): 1920–1928.
- Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008 Sep 2; 71(10): 743–749.
- Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003 Aug 26; 61(4): 487–492.
- Whitwell JL, Dickson DW, Murray ME, Weigand SD, Tosakulwong N, Senjem ML, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case–control study. Lancet Neurol 2012; 11(10): 868–877.
- Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10(9): 785–796.
- Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003 Oct; 2(10): 605–613.
- Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009 Apr; 65(4): 403–413.
- Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009 Mar; 66(3): 382–389.
- Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004 Mar; 55(3): 306–319.
- Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010 Jun; 51(6): 913–920.
- Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010 Sep; 68(3): 319–329.
- Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008 Feb; 7(2): 129–135.
- Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med 2013 Jun; 54(6): 880–886.
- Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008 Jun; 131(Pt 6): 1630–1645.
- Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011 Jan 19; 305(3): 275–283.
- Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008 Oct; 64(4): 388–401.
- Rosenbloom MH, Alkalay A, Agarwal N, Baker SL, O'Neil JP, Janabi M, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011 May 24; 76(21): 1789–1796.
- Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79(6): 1094–1108.
- Xia C, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18 F] T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimer's Dement 2013 Nov; 9(6): 666–676.
- Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014 Jun; 137(Pt 6): 1762–1771.
- Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol 1982 Jun; 11(6): 592–598.
- Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010 Dec 14; 75(24): 2204–2211.
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011 Mar 15; 76(11): 1006–1014.
- Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. Brain 2014 Apr; 137(Pt 4): 1176–1192.
- Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol 2010 Feb; 6(2): 88–97.
- Gefen T, Gasho K, Rademaker A, Lalehzari M, Weintraub S, Rogalski E, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain 2012 May; 135(Pt 5): 1554–1565.
- Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol 2012; 11(2): 170–178.
- Tang-Wai D, Lewis P, Boeve B, Hutton M, Golde T, Baker M, et al. Familial frontotemporal dementia associated with a novel presenilin-1 mutation. Dement Geriatr Cogn Disord 2002; 14(1): 13–21.
- McMonagle P, Deering F, Berliner Y, Kertesz A. The cognitive profile of posterior cortical atrophy. Neurology 2006 Feb 14; 66(3): 331–338.
- Aresi A, Giovagnoli AR. The role of neuropsychology in distinguishing the posterior cortical atrophy syndrome and Alzheimer's disease. J Alzheimers Dis 2009; 18(1): 65–70.
- Whitwell JL, Jack CR, Jr, Kantarci K, Weigand SD, Boeve BF, Knopman DS, et al. Imaging correlates of posterior cortical atrophy. Neurobiol Aging 2007 Jul; 28(7): 1051–1061.
- Lehmann M, Ghosh PM, Madison C, Laforce R, Corbetta-Rastelli C, Weiner MW, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136(3): 844–858.
- Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Tang-Wai DF, Drubach DA, et al. Visual hallucinations in posterior cortical atrophy. Arch Neurol 2006 Oct; 63(10): 1427–1432.
- Hof PR, Archin N, Osmand AP, Dougherty JH, Wells C, Bouras C, et al. Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report. Acta Neuropathol 1993; 86(3): 215–223.
- Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999 Oct; 56(10): 1233–1239.
- Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS. Clinicopathologic differences among patients with behavioral variant frontotemporal dementia. Neurology 2013 Feb 5; 80(6): 561–568.
- Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005 Sep; 128(Pt 9): 1996–2005.
- Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett H, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006; 59(6): 952–962.
- Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain J Neurol 2015 Epub 2015/07/05.
- Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999 Feb; 66(2): 184–188.
- Ikeda M, Ishikawa T, Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2004; 17(4): 265–268.
- Raux G, Gantier R, Thomas-Anterion C, Boulliat J, Verpillat P, Hannequin D, et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology 2000 Nov 28; 55(10): 1577–1578.
- Kramer JH, Jurik J, Sha SJ, Rankin KP, Rosen HJ, Johnson JK, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003 Dec; 16(4): 211–218.
- Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004 Sep; 56(3): 399–406.
- Woodward M, Jacova C, Black SE, Kertesz A, Mackenzie IR, Feldman H, et al. Differentiating the frontal variant of Alzheimer's disease. Int J Geriatr Psychiatry 2010 Jul; 25(7): 732–738.
- Back-Madruga C, Boone KB, Briere J, Cummings J, McPherson S, Fairbanks L, et al. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. Clin Neuropsychol 2002 Aug; 16(3): 331–340.
- Jenner C, Reali G, Puopolo M, Silveri MC. Can cognitive and behavioral disorders differentiate frontal variant-frontotemporal dementia from Alzheimer's disease at early stages? Behav Neurol 2006; 17(2): 89–95.
- Habek M, Hajnsek S, Zarkovic K, Chudy D, Mubrin Z. Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation. Can J Neurol Sci 2010 Jan; 37(1): 118–120.
- Taylor KI, Probst A, Miserez AR, Monsch AU, Tolnay M, Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nat Clin Pract Neurol 2008 Apr; 4(4): 226–232.
- Larner AJ. “Frontal variant Alzheimer's disease”: a reappraisal. Clin Neurol Neurosurg 2006 Oct; 108(7): 705–708.
- Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007 Apr 10; 68(15): 1205–1212.
- Whitwell JL, Jack CR, Jr, Przybelski SA, Parisi JE, Senjem ML, Boeve BF, et al. Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiol Aging 2011 Sep; 32(9): 1531–1541.
- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011 Sep; 134(Pt 9): 2456–2477.
- (a) Ling H, O'Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010 Jul; 133(Pt 7): 2045–2057; (b) McKeith IG. 2006. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9: 417–423.
- Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009 Aug 15; 24(11): 1593–1599.
- Hu WT, Rippon GW, Boeve BF, Knopman DS, Petersen RC, Parisi JE, et al. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord 2009 Jul 15; 24(9): 1375–1379.
- Hu WT, Rippon GW, Boeve BF, Knopman DS, Petersen RC, Parisi JE, et al. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord 2009; 24(9): 1375–1379.
- Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999 Mar 6; 318(7184): 633–638.
- Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 study group. BMJ 2000 Dec 9; 321(7274): 1445–1449.
- Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21(5–6): 353–363.
- Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003 Apr 3; 348(14): 1333–1341.
- Lingler JH, Martire LM, Schulz R. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc 2005 Jun; 53(6): 983–990.
- Beusterien KM, Thomas SK, Gause D, Kimel M, Arcona S, Mirski D. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 2004; 18(15): 1143–1148.
- Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14; 57(3): 481–488.
- Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 Jan 25; 1(1): CD005593.
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 Jan 21; 291(3): 317–324.
- Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009 Jun; 80(6): 600–607.
- Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992 Aug; 86(2): 138–145.
- Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003 Jul; 60(7): 737–746.
- Mizukami K, Tanaka Y, Asada T. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2006 Sep 30; 30(7): 1342–1346.
